

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	<p>DEBORAH J KUHN ET AL: "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 9, 1 November 2007 (2007-11-01), pages 3281-3290, XP002679911, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2007-01-065888 [retrieved on 2007-06-25]</p> <p>* page 3281, right-hand column, paragraph 2 *</p> <p>* page 3286, right-hand column, paragraph 2 *</p> <p>* page 3288; figure 6 *</p> <p>* abstract *</p>	1-14	<p>INV. C12Q1/68 G01N33/53 A61K31/5375 A61K31/69 A61P35/00 A61K38/05 A61K38/07 A61K31/55 C12Q1/6886 G01N33/574</p>
Y	<p>-----</p> <p>WO 2013/058691 A1 (VIVOLUX AB [SE]; LINDER STIG [SE]; LARSSON ROLF [SE]) 25 April 2013 (2013-04-25)</p> <p>* page 3, line 17 - line 20 *</p> <p>* page 7; table 2 *</p> <p>* page 9, line 5 - line 8 *</p> <p>* figure 3f *</p> <p>* claims 1-26 *</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-14	<p>TECHNICAL FIELDS SEARCHED (IPC)</p> <p>A61K A61P</p>
<p>The supplementary search report has been based on the last set of claims valid and available at the start of the search.</p>			
Place of search		Date of completion of the search	Examiner
Munich		18 January 2018	Young, Astrid
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	L. ZHANG ET AL: "In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 11, 1 November 2013 (2013-11-01), pages 2494-2504, XP055441850, US ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0156 * page 2497, right-hand column * * page 2499, right-hand column, paragraph 2 - page 2500, left-hand column, paragraph 1 * * abstract *	1-14	
Y	ERIKA SUZUKI ET AL: "Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells", PLOS ONE, vol. 6, no. 12, 22 December 2011 (2011-12-22), page e27996, XP055266753, DOI: 10.1371/journal.pone.0027996 * page 2, left-hand column, paragraph 2 * * page 3, right-hand column, last paragraph - page 4, right-hand column * * page 5, left-hand column, paragraph 1 - right-hand column, paragraph 3 * * page 7, right-hand column, paragraph 1 * * page 8, left-hand column, last paragraph *	1-14	TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 18 January 2018	Examiner Young, Astrid
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

1
EPO FORM 1503 03 82 (P04C04)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 15 81 4450

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-01-2018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013058691 A1	25-04-2013	AU 2012326682 A1	01-05-2014
		BR 112014009365 A2	18-04-2017
		CA 2852518 A1	25-04-2013
		CL 2014000998 A1	10-10-2014
		CN 104271557 A	07-01-2015
		EA 201490800 A1	30-09-2014
		EP 2780326 A1	24-09-2014
		HK 1203194 A1	23-10-2015
		IL 232118 A	30-06-2016
		JP 6165748 B2	19-07-2017
		JP 2014530852 A	20-11-2014
		KR 20140078742 A	25-06-2014
		MX 345467 B	01-02-2017
		NZ 624019 A	29-07-2016
		SG 11201401608P A	30-07-2014
		US 2014228354 A1	14-08-2014
		WO 2013058691 A1	25-04-2013
ZA 201403302 B	27-05-2015		

专利名称(译)	用于鉴定和治疗对蛋白酶体抑制剂治疗具有抗性的哺乳动物的方法和材料		
公开(公告)号	EP3164506A4	公开(公告)日	2018-02-28
申请号	EP2015814450	申请日	2015-07-01
[标]申请(专利权)人(译)	梅约医学教育与研究基金会		
申请(专利权)人(译)	梅奥基金会的医学教育和研究		
当前申请(专利权)人(译)	梅奥基金会的医学教育和研究		
[标]发明人	MILLER KENA C PAULUS ANEEL CHITTA KASYAPA ASHER ALBAN CHANAN KHAN		
发明人	MILLER, KENA C. PAULUS, ANEEL CHITTA, KASYAPA ASHER ALBAN, CHANAN-KHAN		
IPC分类号	C12Q1/68 G01N33/53		
CPC分类号	A61K38/05 A61K31/5375 A61K31/55 A61K31/69 A61K38/07 A61P35/00 C12Q1/6886 C12Q2600/106 C12Q2600/158 G01N33/574 G01N33/57407 G01N2333/47		
优先权	62/019646 2014-07-01 US		
其他公开文献	EP3164506A1		
外部链接	Espacenet		

摘要(译)

该文献提供了鉴定具有血管癌的哺乳动物 (例如, 骨髓瘤或淋巴瘤, 包括WM, MCL和DLBCL) 的方法和材料, 所述哺乳动物对用蛋白酶体抑制剂例如硼替佐米 (例如, VELCADE) 治疗具有抗性以及方法。和涉及治疗具有对蛋白酶体抑制剂如硼替佐米 (例如, VELCADE) 具有抗性的血癌的哺乳动物的材料。例如, 使用PSMB9 /β1i核酸的表达水平来鉴定哺乳动物具有对蛋白酶体治疗具有抗性的血癌 (例如, 骨髓瘤或淋巴瘤, 例如WM, MCL或DLBCL) 的方法和材料。提供了诸如硼替佐米 (例如, VELCADE) 的抑制剂。

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to class	CLASSIFICATION OF THE APPLICATION (IPC)
Y	DEBORAH J KUHN ET AL: "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma." BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 9, 3 November 2007 (2007-11-01), pages 3281-3286. XRefID: 99811, ISSN: 0006-4971, DOI: 10.1182/blood-2007-01-065888 [retrieved on 2007-06-29] * page 3281, right-hand column, paragraph 2 * page 3286, right-hand column, paragraph 2 * abstract *	1-14	INV. C12Q1/68 G01N33/53 A61K31/5375 A61K31/69 A61P35/00 A61K38/05 A61K38/07 A61K31/55 C12Q1/6886 G01N33/574
Y	WO 2013/098691 A1 (VIVOLUX AB (SE); LINDER STIG (SE); LARSSON ROLF (SE)) 25 April 2013 (2013-04-25) * page 3, line 17 - line 20 * * page 9, line 2 * * page 9, line 5 - line 8 * * figure 3f, * * claims 1-26 * ----- /-/-	1-14	TECHNICAL FIELD AG1K AG1P
The supplementary search report has been based on the list of claims valid first available at the start of the search.			
Date of report: Munich		Date of completion of the search: 18 January 2018	Examiner: Young, Astrid
CATEGORY OF CITED DOCUMENTS: C: prior art document (not a patent document) D: other literature (including patent documents) E: patent document (including patent applications) F: document cited in prior art document G: document cited in prior art document H: member of the same patent family, corresponding document I: member of the same patent family, corresponding document			